| **Objective 1:** Increase awareness and understanding of antimicrobial resistance, its implications and actions to combat it, through effective communication, education and training |
| --- |
| **Activity** | **Responsibility – Lead** | **Key partners (include role)** | **Milestones** | **Expected Outcome/s** | **Links with other Strategy Objectives** |
| ***Priority Action Area 1.1 – Strengthen consumer awareness initiatives to improve understanding of antimicrobial resistance and the importance of using antibiotics appropriately*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 1.2 – Increase support for human and animal health professionals in reinforcing key messages with patients and clients*** |
|  |  |  |  |  | 2.2 |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 1.3 – Strengthen communication and education initiatives for health professionals and team members*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 1.4 – Develop a stakeholder engagement and communication plan to support whole-of-society awareness of, and participation in, implementation of the Strategy*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

| **Objective 2:** Implement effective antimicrobial stewardship practices across human health and animal care settings to ensure the appropriate and judicious prescribing, dispensing and administering of antimicrobials |
| --- |
| **Activity** | **Responsibility – Lead** | **Key partners (include role)** | **Milestones** | **Expected Outcome/s** | **Links with other Strategy Objectives** |
| ***Priority Action Area 2.1 - Ensure that tailored, evidence-based antibiotic prescribing guidelines are available for all sectors*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 2.2 – Ensure the availability of evidence-based, best practice and nationally consistent approaches to AMS across human health and animal health sectors*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 2.3 – Develop tailored, evidence-based resources to support the implementation of AMS programmes*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 2.4 – Review existing accreditation and quality assurance programmes to ensure they appropriately support and encourage compliance with best practice AMS approaches*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 2.5 – Strengthen existing measures to better support appropriate and judicious use of antibiotics*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

| **Objective 3:** Develop nationally coordinated One Health surveillance of antimicrobial resistance and antimicrobial usage |
| --- |
| **Activity** | **Responsibility – Lead** | **Key partners (include role)** | **Milestones** | **Expected Outcome/s** | **Links with other Strategy Objectives** |
| ***Priority Action Area 3.1 – Establish the foundations for national One Health Surveillance*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 3.2 – Agree the objectives of surveillance for each sector, ensuring they align with the overarching objectives for the national One Health surveillance system***  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 3.3 – Develop lists of priority organisms and associated antimicrobials for national reporting*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 3.4 – Agree and implement a uniform standard for laboratory testing methods for resistance susceptibility*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 3.5 – Improve human health surveillance*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 3.6 – Improve animal health and agriculture surveillance*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 3.7 - Investigate requirements for surveillance in food*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

| **Objective 4:** Improve infection prevention and control measures across human health and animal care settings to help prevent infections and the spread of resistance |
| --- |
| **Activity** | **Responsibility – Lead** | **Key partners (include role)** | **Milestones** | **Expected Outcome/s** | **Links with other Strategy Objectives** |
| ***Priority Action Area 4.1 – Ensure availability of evidence-based, best-practice and nationally consistent standards for IPC across human health and animal care settings*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 4.2 - Review existing accreditation and quality assurance programmes to ensure they appropriately support and encourage compliance with best practice IPC measures*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 4.3 - Develop additional initiatives and resources to strengthen IPC in all human health care settings*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 4.4 - Further develop initiatives and resources to strengthen IPC in the livestock industry*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 4.5 - Further develop resources to strengthen IPC in veterinary practice*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 4.6 – Encourage continued increases in vaccination rates to prevent infections*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

| **Objective 5:** Agree a national research agenda and promote investment in the discovery and development of new products and approaches to prevent, detect and contain antimicrobial resistance |
| --- |
| **Activity** | **Responsibility – Lead** | **Key partners (include role)** | **Milestones** | **Expected Outcome/s** | **Links with other Strategy objectives** |
| ***Priority Action Area 5.1 - Identify current gaps and agree national research and development priorities*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 5.2 – Coordinate national research activities and the sharing of information*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 5.3 – Explore opportunities to increase support for research and development, including incentives for greater private sector engagement*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 5.4 – Explore opportunities to support the translation of promising research findings into new products, policies and approaches*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

| **Objective 6:** Strengthen international partnerships and collaboration on regional and global efforts to respond to antimicrobial resistance |
| --- |
| **Activity** | **Responsibility – Lead** | **Key partners (include role)** | **Milestones** | **Expected Outcome/s** | **Links with other Strategy objectives** |
| ***Priority Action Area 6.1 – Active engagement with multilateral organisations and relevant forums to contribute to global action on antimicrobial resistance*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 6.2 – Lead regional initiatives to increase capacity to respond to antimicrobial resistance*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 6.3 – Learn from international best practice*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 6.4 – Participate in international surveillance initiatives*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 6.5 – Establish closer ties with international collaborations to link Australia’s national research agenda with what is happening internationally***  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

| **Objective 7:** Establish and support clear governance arrangements at the local, jurisdictional, national and international levels to ensure leadership, engagement and accountability for actions to combat antimicrobial resistance |
| --- |
| **Activity** | **Responsibility – Lead** | **Key partners (include role)** | **Milestones** | **Expected Outcome/s** | **Links with other Strategy objectives** |
| ***Priority Action Area 7.1 – Identify, establish and maintain linkages between implementation partners across all sectors*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 7.2 – Work with stakeholders to develop an Implementation Plan for the Strategy*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 7.3 – Establish baseline measures to inform monitoring and evaluation of the Strategy***  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| ***Priority Action Area 7.4 – Review regulation (legislated and other) relevant to antimicrobial resistance and antibiotic usage*** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |